A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection – AP-PA02-201 (Tailwind)

Phase: 2

Status: Ongoing

Details
The main purpose of this study is to learn how well the study drug works, how long the study drug stays and works in the airway, and how safe the study drug is when taken alone (or in combination with inhaled antibiotics) compared with placebo and inhaled antibiotics alone.

Sponsor: Armata Pharmaceuticals, Inc.

NCT05616221 - IRB#2021-131